SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Myriad Genetics Inc. (MYGN) on Tuesday reported a loss of $34.1 million in its first quarter.
On a per-share basis, the Salt Lake City-based company said it had a loss of 36 cents. Losses, adjusted for costs related to mergers and acquisitions and stock option expense, were 9 cents per share.
The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 6 cents per share.
The molecular diagnostic company posted revenue of $200.4 million in the period.
Myriad expects full-year revenue in the range of $860 million to $880 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MYGN at https://www.zacks.com/ap/MYGN